For the past 30 years, a dogma of epilepsy treatment has been to start with monotherapy.
central nervous effects of dizziness, ataxia, and sleepiness are probably additive for most combinations. Sodium channel blockers such as phenytoin and carbamazepine often cause dizziness or diplopia in combination, even when the PK interaction works in the opposite direction to increase mutual clearance. On the other hand, a classic PD interaction that is probably synergistic is somnolence with benzodiazepines plus barbiturates, because they have complementary actions on gamma aminobutyric acid (GABA)-mediated chloride channels. Most older drugs fall into only two general categories of major mechanism of action: they are either sodium channel blockers or GABAergic agents. Because of this, there was less flexibility to avoid use of two drugs of the same class and, therefore, less chance of avoiding additive or synergistic PD adverse effects.
The new drugs, while they certainly retain many adverse effects classically associated with older antiepileptic drugs, access newer mechanisms for seizure control. This also opens the door to a wider choice of potential side effects: choosing two drugs with different mechanisms of action will often result in a combination without additive side effects. For example, levetiracetam (a synaptic release inhibitor) rarely causes ataxia, so adding it to phenytoin (a sodium channel blocker) is unlikely to precipitate balance problems. Side effects are not always adverse. Sometimes drug side effects are offsetting. Lamotrigine (a sodium channel blocker) is usually not only non-sedating but actually stimulating, so that using it in combination with a more soporific drug such as pregabalin (a calcium current mediator) is unlikely to produce sleepiness and may actually wake the patient up.
Efficacy of Two Drugs versus One
With regard to efficacy, it is still an open question whether a second monotherapy or a first adjunctive therapy is more likely to control seizures. It cannot be assumed that because two drugs have different mechanisms of action that they will have a complementary salutary effect on seizure control. This is true of both partial-onset and generalized-onset seizures, because almost no trials with this design have been carried out. A very old example is the cross-over trial of valproate versus ethosuximide for absence seizures: in this trial, about the same number of children achieved seizure control with either drug as monotherapy or with the combination, and rates of side effects did not differ. 6 No similar trials of modern drugs have been undertaken.
What do we know? We know that a second monotherapy controls seizures completely in some patients. How many? In an oft-cited trial, it was 47% for the first monotherapy but only 13% for the second. 3 In this trial, only 3% eventually achieved seizure freedom with any adjunctive combination, but apparently combinations were tried only after two or three monotherapies. We do not know how many would have been controlled if adjunctive therapy had been the second option, not the third or fourth. In the only study designed specifically to answer the question of whether adjunctive therapy or alternative therapy was best in patients who had failed only one drug, the seizure-free rates were about the same, at 14-16%.
We still do not know for sure. A few older studies suggested that the combination of phenytoin and phenobarbital is more effective than the combination of phenytoin and carbamazepine. 10 There are suggestive, but not definitive, data that the combination of valproate and lamotrigine is synergistic with regard to seizure control. From these and other animal studies, there is some evidence that drugs with different mechanisms of action are synergistic with regard to potency. These include sodium channel blockers plus GABAergic agents, or α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)-type glutamate receptor blockers with other agents. 12, 13 However, using the same methods, two GABAergic drugs used together were found to be synergistic in some experiments, 13 so the answers remain elusive.
In summary, using two drugs with different major mechanisms of action makes some sense, but cannot be considered truly scientifically rational until we know more. However, avoiding two drugs with significant PK interactions or two drugs with similar PD side effects is a good idea, other considerations being equal. To that extent, rational polytherapy exists. If it is possible to combine two drugs at lower doses than the toxic dose of either with better efficacy, the overall 'drug load,' and thus risk of toxicity, may actually be less than with a high level of a single drug.
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When to Switch and When to Add Based on Efficacy
There are some good reasons to seriously consider 'adding rather than switching'-a course of action heretofore considered heretical.
An earlier resort to polytherapy should be considered as a viable option. 9 However, circumstances will often determine which is best.
Who should be considered for a total switch? If the first drug proves worthless (no improvement in seizures) or is intolerable, the choice is easy. It must be stopped and a second monotherapy started. Who should be considered for an additive regimen? If the first drug is almost, but not quite, completely effective, it makes sense to retain it and to gradually add a second drug to achieve the final summit of seizure control.
The more difficult scenario is when there is a modest effect of the first drug. In that circumstance, a common past practice has been to try to switch over completely to a second monotherapy. However, suppose it requires assumptions about the relative potency of each drug milligram for milligram, and as discussed above this is not clear even from animal studies.
When to Switch and When to AddPatient-related Considerations
Our primary job is to prevent seizures. If a so-called 'breakthrough'
seizure is more likely with a simultaneous switch of drugs, rather than with addition of a new drug to a full dose of the old one, which is almost certainly true, why would we ever do this?
There are some patients for whom it is appropriate: those who are having significant side effects from the first drug; those with newonset or very infrequent seizures, for whom the likelihood of a breakthrough seizure is low and for whom it is important to avoid side effects; and those with 'mild' seizures-such as simple partial events-for whom a breakthrough seizure would not be disastrous.
Other than these patients, then, it is a better strategy to hold the first drug at a therapeutic dose, or at least at the patient's currently tolerated dose, and to add the second drug gradually to a 'full target dose.' The full target dose may or may not be the dose recommended by the manufacturer for adjunctive therapy; it is often less because with experience physicians often find that lower doses are effective and better tolerated.
Once the second drug reaches the target dose, the next question 
Conclusions
The answer to the question posed in the title is 'yes': we should reconsider the practice of second or third monotherapy treatment sequences for epilepsy because early polytherapy is often effective and well-tolerated with the new generation of drugs. However, this must be a qualified 'yes,' because there are categories of patients for whom serial monotherapy remains a better strategy. We certainly need more research on this issue.
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In our actual practice at our epilepsy center, 66% of patients are taking two or more antiepileptic drugs. However, this is a refractory patient population and it must be emphasized that most patients in community neurology practice can and should be treated with monotherapy. 2 For most of these, though, this monotherapy will be the very first drug tried, or at least the very first drug tolerated. Not many will be on a monotherapy agent after failure of two or more drugs because of lack of efficacy. 3, 18 These patients tend to be refractory, and most will end up on combination therapy. This is not such a bad thing, and does not signify physician failure. The new drugs combine more easily for several reasons, so 'polypharmacy'
should not be such a pejorative term. More often heard today is the term 'polytherapy,' and rightly so. n 
